familymednews.com
Countless breast cancer patients in the future will be spared millions of dollars of chemotherapy thanks in part to something that millions of Americans did that cost them just pennies: bought a postage stamp. Proceeds from the U.S. Postal Service’s breast cancer stamp put researchers over the top when they were trying to get enough money to do the landmark […]
Continue reading »
It’s that time of June again: when we celebrate all the incredible dads, pops, grandpas, gramps and the like in our lives. But finding the perfect gift can feel tricky to say the least. For one thing, how did all the dads we know somehow end up that special mix of goofball and critic that make them really hard to shop […]
Continue reading »
Virtually all cervical cancers are caused by HPV, or human papillomavirus, dubbed the “common cold” of sexually transmitted infections because nearly every sexually active person catches it. Fortunately, the immune system vanquishes the majority of HPV infections, with only a small percentage progressing to precancer and, ultimately, cancer. But why do some people clear the infection while others are unable […]
Continue reading »
New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node¬-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more […]
Continue reading »
When it first starts to develop, the heart is a simple tube. Reporting in the journal Nature Communications, researchers at MDC have now described how it forms itself into a its characteristic S-shape and how the ventricles and atria finally develop. Their findings will help scientists to better understand the development of congenital heart diseases. In Germany, nearly one child […]
Continue reading »
Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib show an overall response rate of 41.9 percent, with median progression free survival of 8.2 months. Twenty-four percent of patients achieved a complete response. The gene IDH1 […]
Continue reading »
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. The multi-center Phase I trial, led by researchers at The University of Texas MD Anderson Cancer Center, was designed to determine ivosidenib’s safety and […]
Continue reading »
When the blood supply is low, cancer cells can use lipid molecules as fuel instead of blood glucose. This has been shown in animal tumour models by researchers at Karolinska Institutet, Sweden, in a study published in Cell Metabolism. The mechanism may explain why tumours often develop resistance to cancer drugs that inhibit the formation of blood vessels. Tumour growth […]
Continue reading »
New, improved ways to fight hypertension and low blood pressure may be in the offing, thanks to a discovery of how blood pressure is controlled. National University of Singapore researchers have found a new means of controlling blood pressure that involves the protein galectin-1, present in blood vessels and various other tissues. The researchers showed that galectin-1 reduces the activity […]
Continue reading »
People with a gene variant called APOE4 have a higher risk of developing late-onset Alzheimer’s disease: APOE4 is three times more common among Alzheimer’s patients than it is among the general population. However, little is known about why this version of the APOE gene, which is normally involved in metabolism and transport of fatty molecules such as cholesterol, confers higher […]
Continue reading »